Home » Stocks » Avadel Pharmaceuticals

Avadel Pharmaceuticals PLC (AVDL)

Stock Price: $5.03 USD -0.14 (-2.71%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $5.10 +0.07 (1.39%) Oct 21, 7:47 PM

Stock Price Chart

Key Info

Market Cap 292.85M
Revenue (ttm) 47.56M
Net Income (ttm) 18.41M
Shares Out 58.22M
EPS (ttm) 0.43
PE Ratio 11.70
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $5.03
Previous Close $5.17
Change ($) -0.14
Change (%) -2.71%
Day's Open 5.16
Day's Range 5.01 - 5.22
Day's Volume 267,805
52-Week Range 3.41 - 13.49

More Stats

Market Cap 292.85M
Enterprise Value 181.82M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 58.22M
Float 54.59M
EPS (basic) 0.24
EPS (diluted) 0.43
FCF / Share -0.65
Dividend n/a
Dividend Yield n/a
Earnings Yield 8.55%
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.04M
Short Ratio 3.52
Short % of Float 7.39%
Beta 1.32
PE Ratio 11.70
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.16
PB Ratio 1.74
Revenue 47.56M
Operating Income 24.76M
Net Income 18.41M
Free Cash Flow -35.09M
Net Cash 111.03M
Net Cash / Share 1.91
Gross Margin 99.02%
Operating Margin 52.07%
Profit Margin 38.70%
FCF Margin -73.78%
ROA -4.22%
ROE 22.40%
ROIC 8.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(255.47% upside)
Current: $5.03
Target: 17.88
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-42.66%-40.39%15.31%-13.16%1055.32%258.34%-44.53%-76.89%-12.12%-
Gross Profit47.0985.7515713716211.593.627.1326.3230.18
Operating Income-23.27-12858.4744.32102-33.15-25.57-28.75-9.58-9.84
Net Income-33.23-95.3068.27-41.2841.80-85.47-42.93-3.23-8.77-8.98
Shares Outstanding37.4037.3340.4741.2540.5836.2125.4525.1424.6724.41
Earnings Per Share-0.89-2.551.63-1.000.96-2.36-1.69-0.13-0.36-0.37
Operating Cash Flow-38.33-82.7216.6618.9084.29-10.62-20.68-23.14-10.32-5.46
Capital Expenditures0.13-0.18-0.59-1.20-1.6311.51-0.02-1.00-1.72-3.47
Free Cash Flow-38.20-82.8916.0717.7082.660.90-20.70-24.14-12.04-8.93
Cash & Equivalents64.1699.9294.0815414592.837.049.1624.4931.34
Total Debt12513574.191361.123.7285.5536.894.064.06
Net Cash / Debt-60.49-35.3319.8918.2114489.12-78.51-27.7320.4327.29
Book Value-29.202.7885.5842.0769.1324.90-9.5130.5029.7936.31
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Avadel Pharmaceuticals PLC
Country Ireland
Employees 50
CEO Gregory J. Divis

Stock Information

Ticker Symbol AVDL
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: AVDL
IPO Date June 7, 1996


Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.